Dr. Vicki Nienaber has been a leader in the fragment-based drug discovery field since its inception at Abbott laboratories during the 1990's. At Abbott, she worked alongside NMR screeners pairing SARbyNMR with x-ray for drug discovery and is primary inventor of the first crystallographic screening method still in use today. Dr. Nienaber has led numerous programs including SGX collaborations with Eli Lilly, Novartis and SGX internal FBLD pipeline. Dr. Nienaber also built the fragment screening platform at Abbott laboratories including invention of the first crystal mounting robot (ACTOR, now marketed by Rigaku). She also fully implimented the structural biology platform at SGX coordinating between engineers, programmers and scientists.
Starting Small and Staying Small: A Guiding Principle for Fragment Library Design and Fragment Optimization for Drug-like Properties
Thursday, 29 September 2016 at 16:30
Add to Calendar ▼2016-09-29 16:30:002016-09-29 17:30:00Europe/LondonStarting Small and Staying Small: A Guiding Principle for Fragment Library Design and Fragment Optimization for Drug-like PropertiesIn Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
“It can scarcely be denied that the supreme goal of all theory is to make the irreducible basic elements as simple and as few as possible without having to surrender the adequate representation of a single datum of experience,” later simplified to “Everything should be made as simple as possible but not one bit simpler.” ---- Albert Einstein
This is a guiding principle in science and easily applied to the field of fragment-based lead discovery. Since its inception in the mid-1990 by Abbott laboratory scientists, it has grown into an accepted world-wide method of drug discovery. The number of metrics has grown, as have the number of approaches, and library molecular weights, sizes and shapes. At Zenobia Therapeutics and our products division, Zenobia Fragments, we have taken a step back and sought to distill FBLD down its basic scientific principles and guidelines. We will discuss our library design process and criteria, screening strategy including number of compounds screened and approach to optimization where a specific, bioavailable and efficacious LRRK2 inhibitor was identified with synthesis of less than 50 compounds.
Add to Calendar ▼2016-09-29 00:00:002016-09-30 00:00:00Europe/LondonIn Silico Drug Discovery and Predictive Toxicology 2016In Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2016-09-29 16:30:002016-09-29 17:30:00Europe/LondonStarting Small and Staying Small: A Guiding Principle for Fragment Library Design and Fragment Optimization for Drug-like PropertiesIn Silico Drug Discovery and Predictive Toxicology 2016 in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
